Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial.
William A MurphyNan LinAmy DamaskGregory G SchwartzPhillippe Gabriel StegMichael SzarekPoulabi BanerjeeSergio FazioGaren ManvelianRobert PordyAlan R ShuldinerCharles PauldingPublished in: Circulation. Genomic and precision medicine (2022)
This study comprises the largest discovery exome-wide and genome-wide association study for atorvastatin- or rosuvastatin-mediated SAMS to date. These novel genetic findings may provide biological/mechanistic insight into this drug-induced toxicity, and help identify at-risk patients before selection of lipid-lowering therapies.
Keyphrases
- drug induced
- liver injury
- genome wide association study
- end stage renal disease
- newly diagnosed
- cardiovascular disease
- oxidative stress
- type diabetes
- copy number
- coronary artery disease
- small molecule
- high throughput
- study protocol
- genome wide
- peritoneal dialysis
- metabolic syndrome
- phase iii
- patient reported outcomes
- weight loss